Telik Telcyta vs. Iressa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Telik initiates a Phase III registration trial comparing its apoptosis-inducing oncologic Telcyta to AstraZeneca's Iressa for single-agent, third-line treatment of non-small cell lung cancer. ASSIST-2 (Assessment of Survival In Solid Tumors-2) will randomize 520 patients to either Telcyta (TLK286) or Iressa (gefitinib); endpoints include survival, time to tumor progression and objective response rate. Another registration trial, in women with resistant ovarian cancer (ASSIST-1), is underway. Other ongoing studies include combination regimens in NSCLC and ovarian cancer, and a single-agent study in previously untreated metastatic breast cancer. ASSIST-1 and -2 are both under special protocol assessments with FDA, Telik notes. Telcyta has fast-track designation for both indications...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.